Table 2.

Treatment status

		Zoledronic acid (n=981)	Clodronic acid (n=979)
Follow-up (years)		3·7 (2·8–4·7)	3·8 (2·9–4·7)
Still receiving bisphosphonate		111 (11%)	132 (13%)
Administration of bisphosphonate not confirmed		54 (6%)	36 (4%)
Discontinued study before disease progression		235 (24%)	185 (19%)
Disease progression or death		581 (59%)	626 (64%)
Time on treatment (days)
	Intensive pathway	396 (152–737)	409 (152–727)
	Non-intensive pathway	320 (138–520)	306 (111–505)

Data are median (IQR) or number (%).